Last reviewed · How we verify
NCT06892379
A Study of HS-20110 in Participants With Advanced Solid Tumors
Phase 1 trial testing HS-20110 (Phase Ia：Dose escalation ) in Solid Tumors in 475 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Hansoh BioMedical R&D Company |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 475 |
| Start date | 26 February 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 September 2027 |
| Sites | 6 locations across China, United States |
Drugs / interventions tested
- HS-20110 (Phase Ia：Dose escalation ) — full drug profile →
- HS-20110 (Phase Ib:Dose expansion ) — full drug profile →
Conditions studied
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Hansoh BioMedical R&D Company — full company profile →
Who can join
18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06892379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumors
Currently open trials in the same condition.
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
- NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting
Other Hansoh BioMedical R&D Company trials
Trials by the same sponsor.
- NCT07464327 — A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With A · Phase 3 · not yet recruiting
- NCT07462923 — HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · Phase 1 · recruiting
- NCT07283367 — A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. · Phase 1, PHASE2 · not yet recruiting
- NCT07186452 — Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06844799 — A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06892379 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hansoh BioMedical R&D Company
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06892379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing